title: Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.
abstract: OBJECTIVE
  To evaluate the efficacy of weight changes from baseline of the sodium-glucose cotransporter 2 (SGLT2) inhibitors treatment and glucagon-like peptide-1 (GLP-1) analogs treatment after comparisons with a placebo in type 2 diabetes patients, and the associated factors.
  
  
  METHODS
  Studies were searched from when recording began, June 2004, until June 2015, and re-searched in July 2016, and placebo-controlled randomized trials in type 2 diabetes patients with a study length of ≥12 weeks were included.
  
  
  RESULTS
  A total of 97 randomized controlled trials were included. Compared with a placebo, treatment with SGLT2 inhibitors was associated with a significantly greater decrease in weight change from baseline (weighted mean differences -2.01 kg, 95% confidence interval -2.18 to -1.83 kg, P < 0.001). Compared with a placebo, changes with GLP -1 treatment were also associated with a comparable decrease in weight change from baseline (weighted mean differences -1.59 kg, 95% confidence interval -1.86 to -1.32 kg, P < 0.001). Meta-regression analysis showed that the baseline age, sex, baseline glycated hemoglobin, diabetes duration or baseline body mass index were not associated with the weight change from baseline in SGLT2 inhibitors or in GLP-1 treatment corrected by placebo. Comparisons of weight changes from baseline corrected by placebo between SGLT2 inhibitors and GLP-1 treatment showed that the difference was not significant (P > 0.05).
  
  
  CONCLUSIONS
  According to the present meta-analysis, treatment with SGLT2 inhibitors and treatment with GLP-1 analogs led to comparable weight changes from baseline, which are both with significance when compared with placebo treatment.
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Cai
authors.affiliation: Department of Pharmacy, National Center of Gerontology, Beijing Hospital, Beijing, China.
authors.forename: Liwei
authors.initials: L
authors.lastname: Ji
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Yifei
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Wenjia
authors.initials: W
authors.lastname: Yang
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Lingli
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Xueyao
authors.initials: X
authors.lastname: Han
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Simin
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Endocrine & Metabolism Department, Peking University People's Hospital, Beijing, China.
authors.forename: Linong
authors.initials: L
authors.lastname: Ji
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D052216:Glucagon-Like Peptide 1
keywords: Bodyweight; Glucagon-like peptide-1 analogs; Sodium-glucose cotransporter 2 inhibitors